A Phase II, Multicenter, Open-label, Three-cohort Trial Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma (BCC)

Trial Profile

A Phase II, Multicenter, Open-label, Three-cohort Trial Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma (BCC)

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Apr 2015

At a glance

  • Drugs Vismodegib (Primary)
  • Indications Basal cell cancer
  • Focus Therapeutic Use
  • Sponsors Genentech
  • Most Recent Events

    • 22 May 2014 As per NCT official title get changed from 2 cohort to 3 cohort and hence number of treatment arms changed from 2 to 3.
    • 01 May 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 05 Apr 2013 Planned End Date changed from 1 Dec 2012 to 1 Aug 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top